Press Releases Year None2021202020192018201720162015201420132012 Apr 12 Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19 Apr 12 Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab) Apr 9 NIH COVID-19 Treatment Guidelines Strongly Recommend Use of REGEN-COV™ (casirivimab with imdevimab) in Outpatients at High Risk of Clinical Progression Apr 6 Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021 Mar 30 NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients Mar 23 Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients Mar 17 Teen Scientists Win $1.8 Million at Virtual Regeneron Science Talent Search 2021 for Remarkable Research on Infinite Matching Algorithms, Machine Learning to Evaluate New Medicines and Water Filtration Mar 15 Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival Mar 4 FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma Feb 27 Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma Current page 1 Page 2 Page 3 Next page › Last page »